BPC-157 Complete Guide: All Forms, Routes, Doses & Research
Definitive reference for BPC-157 — covering all forms (free base, arginate, stable), administration routes, preclinical research, and mechanisms of action.
Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It is one of the most extensively studied healing peptides in preclinical research, with over 100 published studies demonstrating tissue-protective and regenerative effects across multiple organ systems.
Forms of BPC-157
| Form | Full Name | Key Difference | Stability |
|---|---|---|---|
| BPC-157 (Acetate) | BPC-157 acetate salt | Standard research form; acetate counter-ion | Good in solution at pH 7; sensitive to extreme pH |
| BPC-157 Arginate | BPC-157 arginine salt | Arginine counter-ion; proposed enhanced stability | Improved stability profile vs. acetate in some conditions |
| BPC-157 Stable | Stabilized BPC-157 analog | Structural modifications for protease resistance | Enhanced resistance to enzymatic degradation |
| BPC-157 / TB-500 Blend | Combination formulation | Synergistic with thymosin beta-4 fragment | Dependent on storage conditions |
Sequence & Properties
- Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Molecular Weight: 1419.53 Da
- CAS Number: 137525-51-0
- Amino Acids: 15 (pentadecapeptide)
- Origin: Partial sequence of human gastric juice protein BPC
Mechanism of Action
BPC-157 operates through multiple parallel pathways:
-
NO System Modulation: Interacts with the nitric oxide system, promoting vasodilation and angiogenesis. Studies show BPC-157 can counteract both NOS-blocker and NOS-substrate effects.
-
VEGF Upregulation: Stimulates vascular endothelial growth factor expression, promoting new blood vessel formation in damaged tissue.
-
FAK-Paxillin Pathway: Activates focal adhesion kinase signaling, promoting cell migration and wound closure.
-
Growth Factor Modulation: Interacts with EGF, FGF, and other growth factor systems to coordinate tissue repair.
-
Dopamine System: Interacts with dopamine receptors and transporters, with implications for neuroprotection and gut-brain axis signaling.
Research by System
Gastrointestinal
BPC-157's origin from gastric juice makes GI research its most extensively studied application:
- Gastric ulcers: Accelerated healing in multiple animal models (Sikiric et al., 1994)
- IBD models: Reduced inflammation and promoted mucosal healing
- Esophageal damage: Protection against acid-reflux induced damage
- Intestinal anastomosis: Improved healing of surgical gut connections
- Fistula healing: Promoted closure in animal models
Musculoskeletal
- Tendon healing: Accelerated Achilles tendon repair in rat models (Chang et al., 2011)
- Ligament repair: Enhanced MCL healing with improved collagen organization
- Muscle injury: Promoted regeneration after crush and transection injuries
- Bone healing: Accelerated fracture repair in rabbit models
Neurological
- Peripheral nerve repair: Enhanced sciatic nerve regeneration after transection
- TBI: Neuroprotective effects in traumatic brain injury models
- Dopaminergic protection: Counteracted MPTP-induced neurotoxicity
- Spinal cord injury: Functional recovery in rat models
Organ Protection
- Liver: Protection against various hepatotoxins (alcohol, NSAIDs, CCl4)
- Kidney: Cytoprotection in nephrotoxicity models
- Heart: Antiarrhythmic effects and protection during ischemia (Barisic et al., 2013)
- Lung: Protection in pulmonary hypertension models
Administration Routes
| Route | Form | Research Context |
|---|---|---|
| Subcutaneous injection | Reconstituted lyophilized powder | Most common research route; systemic delivery |
| Intramuscular injection | Reconstituted lyophilized powder | Local tissue targeting |
| Intraperitoneal injection | Solution | Standard in rodent studies; systemic distribution |
| Oral (per os) | Solution or capsule | Studied for GI conditions; gastric origin supports local activity |
| Topical | Cream formulation | Wound healing, burn research |
| Sublingual | Solution | Limited research; avoids first-pass metabolism |
Oral vs. Injectable
BPC-157 is unusual among peptides in demonstrating biological activity through both oral and injectable routes in animal studies:
- Oral: Particularly effective for GI conditions. The peptide's gastric origin may allow local activity in the GI tract before degradation. Multiple rat studies have shown oral efficacy for gastric ulcers, colitis, and intestinal inflammation.
- Injectable: Preferred for systemic conditions (musculoskeletal, neurological). Subcutaneous injection provides reliable systemic bioavailability.
Synergies & Combinations
BPC-157 + TB-500 (Healing Stack)
The most commonly studied combination. BPC-157 promotes angiogenesis (new blood vessels) while TB-500 promotes cell migration and actin regulation. These complementary mechanisms may accelerate tissue repair synergistically.
BPC-157 + GHK-Cu
BPC-157 provides growth factor modulation and angiogenesis while GHK-Cu contributes extracellular matrix remodeling and anti-inflammatory gene expression. Studied for comprehensive wound healing protocols.
Safety Profile in Research
BPC-157 has shown a wide safety margin in preclinical studies:
- No reported organ toxicity at standard research doses in published studies
- No observed mutagenic or carcinogenic effects in available data
- LD50 has not been reached in toxicology studies (very high therapeutic index)
- No reported hormonal axis disruption
Limitations: All safety data comes from preclinical (animal) studies. No completed human clinical trials have been published to date.
See Also
Research Articles
In-depth research articles on peptide science, comparative analyses, and therapeutic applications.
TB-500 Complete Guide: Thymosin Beta-4 Research, Mechanisms & Protocols
Comprehensive TB-500 (Thymosin Beta-4) reference — mechanisms of action, cardiac repair research, wound healing, anti-inflammatory effects, and all related fragments.